Inclusion Criteria:

          -  Males or females, ≥18 years of age

          -  Must have a confirmed diagnosis of active MM

          -  Must have measurable MM

          -  Must have relapsed / refractory MM, having received treatment with proteasome
             inhibitor and IMiD [Phase 2: Must have relapsed / refractory MM, and refractory to
             last line of therapy, having received treatment with proteasome inhibitor, an IMiD,
             CD38 targeted therapy and undergone autologous stem cell transplant (ASCT) or not a
             candidate for ASCT.]

          -  Must have adequate hepatic, renal, cardiac and hematopoietic function

        Exclusion Criteria:

          -  Is pregnant or lactating

          -  Has inadequate venous access and/or contraindications to leukapheresis

          -  Has active hemolytic anemia, plasma cell leukemia, Waldenstrom's macroglobulinemia,
             POEMS syndrome, disseminated intravascular coagulation, leukostasis, amyloidosis,
             significant autoimmune, CNS or other malignant disease

          -  Has an active second malignancy (not disease-free for at least 5 years) in addition to
             MM, excluding low-risk neoplasms such as non-metastatic basal cell or squamous cell
             skin carcinoma.

          -  Has active autoimmune disease

          -  Has a history of significant central nervous system (CNS) disease, such as stroke,
             epilepsy, etc.

          -  Has an active systemic infection

          -  Has hepatitis B or C virus, human immunodeficiency virus (HIV), or human
             T-lymphotropic virus (HTLV) infection, or any immunodeficiency syndrome.

          -  Has any psychiatric or medical disorder that would preclude safe participation in
             and/or adherence to the protocol

          -  Has receiving immunosuppressive or other contraindicated therapies within the excluded
             time frame from entry

          -  Has CNS metastases or symptomatic CNS involvement

          -  Has a history of having undergone allogeneic stem cell transplantation, or any other
             allogeneic or xenogeneic transplant, or has undergone autologous transplantation
             within 90 days.

          -  Unable to take acetylsalicylic acid (ASA) daily as prophylactic anticoagulation.
             (Cohorts R and RP only).

          -  History of thromboembolic disease within the past 6 months, regardless of
             anticoagulation (Cohorts R and RP only).